Total Funding
70
60
Total FundingSeries B raised
Growth Score
-12 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
21406
Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.
- Don Munoz: Chief Financial OfficerPast Role: Aurion Biotechnologies, Chief Financial Officer
- Miquel Vila-Perelló: CEO and co-founder
About the Company
SpliceBio develops genetic medicines through its innovative Protein Splicing platform, focusing on gene therapies for genetic diseases. The company aims to address conditions caused by mutations in large genes, utilizing proprietary technologies to create novel treatment options. SpliceBio's pipeline includes programs targeting specific
genetic disorders, such as Stargardt Disease. By leveraging its expertise in protein splicing, the company seeks to advance the field of gene therapy and improve patient outcomes. Through ongoing research and development, SpliceBio contributes to the understanding and treatment of complex genetic conditions.
